CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
治疗诊断性嵌合抗原受体（CAR）-T 细胞：对实体瘤近期趋势和挑战的见解
英文原题：Theranostic chimeric antigen receptor (CAR)-T cells: Insight into recent trends and challenges in solid tumors.
查看英文原题
Theranostic chimeric antigen receptor (CAR)-T cells: Insight into recent trends and challenges in solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
细胞疗法在包括癌症在内的多种危及生命的疾病中已达到重要里程碑。使用荧光和放射性标记的嵌合抗原受体（CAR）-T细胞进行细胞疗法是诊断或治疗恶性肿瘤的成功策略。由于细胞疗法方法在癌症中产生不同结果，血液系统癌症的成功尚未转移到实体瘤治疗中，导致更多死亡。因此，细胞疗法平台有许多需要改进的领域。通过细胞追踪和分子成像了解与实体癌相关的治疗障碍，可能为有效将CAR-T 细胞递送到实体瘤中提供平台。本综述描述了CAR-T 细胞在治疗实体瘤和非实体瘤中的作用及最新进展。此外，我们从分子成像和细胞追踪的角度讨论了主要障碍、作用机制、新策略和克服挑战的解决方案。
展开英文摘要原文
Cell therapy has reached significant milestones in various life-threatening diseases, including cancer. Cell therapy using fluorescent and radiolabeled chimeric antigen receptor (CAR)-T cell is a successful strategy for diagnosing or treating malignancies. Since cell therapy approaches have different results in cancers, the success of hematological cancers has yet to transfer to solid tumor therapy, leading to more casualties.
Therefore, there are many areas for improvement in the cell therapy platform. Understanding the therapeutic barriers associated with solid cancers through cell tracking and molecular imaging may provide a platform for effectively delivering CAR-T cells into solid tumors. This review describes CAR-T cells' role in treating solid and non-solid tumors and recent advances.
Furthermore, we discuss the main obstacles, mechanism of action, novel strategies and solutions to overcome the challenges from molecular imaging and cell tracking perspectives.
论文信息
- 作者
- Kheyrolahzadeh K、Tohidkia MR、Tarighatnia A、Shahabi P、Nader ND、Aghanejad A
- 第一作者单位
- Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Nuclear Medicine, Faculty of Medicine, Imam Reza General Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.Iran
- 通讯作者单位
- Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Nuclear Medicine, Faculty of Medicine, Imam Reza General Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: aghanejaday@tbzmed.ac.ir.Iran
- 文献类型
- 综述
- 期刊
- Life sciences2023 Sep 1
- 原文标识
- PubMed 37422069 · DOI 10.1016/j.lfs.2023.121917